Construction of a 19,000m2 facility at its site in Copenhagen is the latest example of the CDMO’s growth strategy. In February 2017, Japan’s AGC Asahi Glass (AGC) acquired CMC Biologics, a contract development and manufacturing organization (CDMO) with facilities in Seattle, Washington, and Copenhagen, Denmark. Later that year, the firm rolled out an expansion at the Danish site adding five 2,000 L single-use bioreactors to be run in single unit operations or in unison. In 2018, the CDMO – now…
